BAYER AG NA O.N.
Commented by Armin Schulz on July 19th, 2023 | 07:45 CEST
Pfizer, Cardiol Therapeutics, Bayer - Pharma facing turnaround despite drug shortages?
In mid-June, there was a shortage of 470 prescription drugs in Germany, according to the Federal Institute for Drugs and Medical Devices. However, not only Germany is suffering from a shortage, but all of Europe. Once again, the dependence on China is the underlying cause. The EU is seeking countermeasures, but this will be challenging because capped prices, bureaucracy and rising energy costs make a location like Germany seem less attractive. At the same time, demographic change means that society needs the pharmaceutical industry more and more urgently. Therefore, we look at three companies that aim to heal sick people.
Read
Commented by Juliane Zielonka on July 13th, 2023 | 07:40 CEST
Defence Therapeutics, Bayer AG, Rheinmetall: Patents, price jump and billions of euros
The global biotechnology market is estimated to grow at a CAGR of 12.8% from 2023 to 2030. This has prompted Defence Therapeutics to secure numerous patents for their innovative platform technology ACCUM™. The platform is the linchpin for therapies in the fight against globally prevalent cancers such as lung, breast, and pancreatic cancer. Defence Therapeutics focuses on strengthening the body's immune system to defend against evil invaders. Cancer is also a topic at Bayer AG. The share price jumps as rumors circulate that the Group intends to divest its agricultural division - including Monsanto and the weedkiller suspected of causing cancer. Rheinmetall can report a further plus. Both the German and Dutch armies are ordering airborne vehicles worth billions. Whether these orders are intended solely for Ukraine will become clearer as the latest news unfolds regarding NATO's activities.
Read
Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST
Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!
In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.
Read
Commented by Juliane Zielonka on June 28th, 2023 | 07:40 CEST
Cardiol Therapeutics, Bayer, BASF - Sensational breakthroughs in medicine and sustainability
A study in the JACC journal shows that cardiovascular risk factors and diseases will increase sharply in the US. Ischemic heart disease is projected to increase by 31.1%, heart failure by 33.0% and myocardial infarction by 30.1%. Cardiol Therapeutics, a Canadian company specializing in cardiovascular diseases, is thus rapidly gaining in importance. Bayer goes AI and partners for the first time with a Swiss hospital for a digital solution that supports radiologists in diagnosis and treatment. BASF invests with its venture arm in the Swiss startup DePoly, which has developed an innovative chemical recycling technology. Discover the sustainable solution behind this investment here.
Read
Commented by Armin Schulz on June 26th, 2023 | 09:20 CEST
Bayer, BioNxt Solutions, BioNTech - Biotech facing a rebound?
Due to the Corona pandemic, the pharmaceutical and biotech sector received a lot of attention. Many investors invested too late and could hardly benefit from the significant upward movements. After the hype, a sense of disillusionment set in. The vaccine manufacturers felt the effects because as soon as the pandemic subsided, the stock market also went down. Large and small companies experienced sell-offs, with some trading below their cash reserves. These low prices led to a wave of takeovers. Most recently, Novartis snapped up the biotech company Chinook for up to USD 3.5 billion. Therefore, today, we look at three companies from the healthcare sector.
Read
Commented by Juliane Zielonka on June 9th, 2023 | 07:30 CEST
Defence Therapeutics, Bayer AG, Palantir Technologies - Networked data revolutionizes the future of production
In the battle against cancer, the Canadian biotech company Defence Therapeutics is focusing on pancreatic cancer cells. They are currently conducting a new study that aims to develop a vaccination against pancreatic cancer. A crucial factor driving this project is the utilization of networked data. Bayer AG is also active in Canada. The Company is partnering with Acuitas to develop new business areas in the field of mRNA-based gene therapy. Palantir Technologies' move to become active in the energy sector is also new. A battery plant in North America serves as a sandbox for this. We provide insight into the latest developments for investors with a growth strategy.
Read
Commented by Fabian Lorenz on June 7th, 2023 | 08:00 CEST
Commodity shares with price potential: Bayer, K+S, and Almonty Industries in the analyst check
There are no signs of a deep recession in the US at the moment, which is positive for commodity prices and the corresponding companies. What do analysts say? They see a price potential of over 170% for tungsten producer Almonty Industries. With the commissioning of the flagship mine in South Korea, revenues and profits should increase strongly from 2024. After K+S earned brilliantly last year, there is a lack of positive impulses this year. Several analysts have spoken out. Can the DAX-listed company make gains again? At Bayer, the euphoria surrounding the change in the board of directors has faded, and the share price is almost back to where it was at the beginning of the year. But analysts see significant upside potential.
Read
Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST
BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns
Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.
Read
Commented by André Will-Laudien on May 16th, 2023 | 09:45 CEST
BioNTech, Bayer, BioNxt, Formycon - The next biotech wave is rolling in - select carefully now!
Even after Corona, the biotech sector remains an interesting investment sector because it is still important to keep an eye on the major widespread diseases. For many companies, this will probably mean a longer waiting game for investors. In addition to the promising research approaches and milestone plans, the cash reserves of these companies are also important. While having ample funding can lead to quick progress in the laboratory, it is crucial to have the necessary liquidity. In refinancing, however, things have become a little frostier since the rise in interest rates. Which companies should be put under the microscope?
Read
Commented by Juliane Zielonka on May 4th, 2023 | 08:50 CEST
Bayer AG, First Phosphate, Porsche - In the fast lane with the right stock mix
Can sustainability and profitability go hand in hand? When looking at First Phosphate, a company that recently went public, this is true. The Company has found its place in the niche of LFP batteries for the global energy transition. Porsche AG also knows that electromobility is winning the race. The eMacan is selling so well that CFO Meschke has set a target return of 19%. Is that what Bayer's new CEO, Bill Anderson, is thinking? The conglomerate of Consumer Health, Crop Science and Pharma has more potential than the market is currently pricing in.
Read